Furthermore, preferential killing of CD44+/CD24−/low breast cancer cells or BCSCs induced by MET can be sufficient to overcome the primary resistance to Herceptin® in HER2+ breast cancer xenografts. This evidence concerns the gene ERBB2 and breast carcinoma.